U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07818486) titled 'A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors' on Sept. 08.
Brief Summary: This Phase Ib/II study is a clinical trial to evaluate the efficacy and safety of BL-M08D1 for Injection in patients with recurrent or metastatic nasopharyngeal carcinoma and other solid tumors.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Nasopharyngeal Carcinoma (NPC)
Solid Tumors
Intervention:
DRUG: BL-M08D1
Administration by intravenous infusion for a cycle of 3 weeks.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Publi...